Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
1996-11-27
2004-03-02
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C424S134100, C424S135100, C435S069700, C530S387300
Reexamination Certificate
active
06699715
ABSTRACT:
BACKGROUND OF THE INVENTION
Naive CD4+ T-cells require two independent signals in order to be successfully activated and capable of undergoing clonal expansion (Janeway,
Cold Spring Harbor Symp. Quant. Biol
. 54:1-14 (1989)). The first signal is achieved by stimulation through the T-cell receptor by immunogenic peptides presented by MHC class II molecules on antigen presenting cells (APC) (Weiss,
J. Clin. Invest
. 86:1015 (1990)).
In addition, a second signal, referred to as costimulation, is also required. This costimulatory signal is generally provided through the ligation of CD28 on the T-cell and its inducible counter-receptor CD80, or CD86 on the APC (Linsley et al,
J. Exp. Med
. 173:721-730 (1991)).
The modified single chain Fv (sFv) molecules of the invention, when expressed on a cell surface, act as artificial co-stimulatory ligands. They were constructed to enhance an immune response to disease.
Others have constructed sFv molecules for purposes of intracellular targeting to combat disease (Biocca and A. Cattaneo, (1995) Trends in Cell Biology 5:248-252). However, the sFv molecules so constructed did not comprise a transmembrane domain which could be anchored to an extracellular surface (Biocca and Cattaneo, supra).
sFv molecules are one example of a myriad of molecules that are being tested for potential therapeutic and diagnostic uses against disease. Additional molecules of this type are needed.
SUMMARY OF THE INVENTION
The modified sFv molecules of the present invention stimulate adhesion between cells thereby enhancing an immune response against disease. These molecules generally comprise a binding site of an antibody and at least a portion of a transmembrane domain of a cell surface receptor.
In one embodiment of the invention, the modified sFv molecule further comprises a linker which connects the binding site to at least a portion of the transmembrane domain. In a specific embodiment, the modified sFv molecule comprises a binding site which recognizes and binds the CD28 receptor, a Fc portion of an antibody, and at least a portion of a transmembrane domain. In this embodiment, the binding site has two variable regions (V
H
and/or V
L
chains) and the Fc portion connects the binding site with the transmembrane domain.
REFERENCES:
patent: 5225538 (1993-07-01), Capon et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5712149 (1998-01-01), Roberts
patent: WO 93 19163 (1993-09-01), None
patent: WO 96 23814 (1996-08-01), None
Isacke et al, the Adhesion Molecule Facts Book, Second Edition, Academic Press, pp. 103 and 111, 2000.*
Janeway, Jr et al, Immunobiology: The Immune System in Health and Disease, Garland Publishing Inc, pp. A1-A10, 1997.*
Lund et al. (1991) J. Immun. 147(8):2657-2662.
Linsley et al. (1991) J. Exp. Med. 173.
Biocca and A. Cattaneo (1995) Trends in Cell Biology 5:248-252.
C.R. Newton, et al. (1994) Protein Expression and Purification 5(5):449-57.
G.F. Tu, et al. (1995) J. of Biol. Chem. 270(16):9322-6.
Hansen et al. (1980) Immunogenetics 10:247-260.
Parham, et al. (1983) J. Immunol. 131:2895-2902.
A. Barclay et al. (1993) Academic Press pp101-269.
Hayden et al. (1996) Tissue Antigen vol. 4.
Waterhouse et al. (1995) Science 270(5238):890, 985-989.
Walunas et al. (1994) Immunity 1:405-413.
Jenkins et al. (1991) J. Immunol. 147(8):2461-2466.
Gimmi et al. (1991) Proc. Natl. Acad. Sci. USA 88:6575-6579.
Azuma et al. (1992) J. Immunol. 149(4):1115-1123.
Azuma et al. (1992) J. Exp. Med. 175:353-360.
Chen et al. (1992) Cell 71:1093-1102.
Chen et al. (1992) J. Immunol. 148(8):2617-2621.
Rosenberg et al. (1986) Science 433:1318-1321.
Abbass et al. Cellular and Molecular Immunology, 2nd Edition, 1994, Chapter 7 pp. 163-164.
Gilliland et al. (1996) “Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments,”Tissue Antigens, 47:1-20.
Fell Perry
Hayden Martha
Ledbetter Jeffrey A.
Mittler Robert
Winberg Gosta
Bristol-Myers Squibb Co.
Klein Christopher A.
Lange Keith R.
Saunders David
LandOfFree
Modified sFv molecules which mediate adhesion between cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified sFv molecules which mediate adhesion between cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified sFv molecules which mediate adhesion between cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3232109